Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil
This article was originally published in The Pink Sheet Daily
FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.
You may also be interested in...
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
Cephalon plans to submit information to FDA within “the next few weeks.”
Johnson & Johnson’s historical strength in immunology will form the foundation of a renewed push in the field, with novel candidates for indications such as psoriasis, arthritis and inflammatory bowel disease.